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ABSTRACT In January 2005, passage of California Senate Bill 1159 enabled California’s
county or city governments to establish disease prevention demonstration projects
(DPDPs) through which pharmacies could subsequently register to legally sell up to 10
syringes to adults without a prescription. California’s 61 local health jurisdictions
(LHJs) were surveyed annually in 2005–2007 to monitor the progress of DPDP
implementation and assess program coverage, facilitators, and barriers. Completed
surveys were returned by mail, fax, e-mail, phone, or internet. We analyzed 2007 survey
data to describe current DPDP status; data from all years were analyzed for trends in
approval and implementation status. By 2007, 17 (27.9%) LHJs approved DPDPs, of
which 14 (82.4%) had registered 532 (17.8%) of the 2,987 pharmacies in these 14
LHJs. Although only three LHJs added DPDPs since 2006, the number of registered
pharmacies increased 102% from 263 previously reported. Among the LHJs without
approved DPDPs in 2007, one (2.3%) was in the approval process, seven (16.3%)
planned to seek approval, and 35 (81.4%) reported no plans to seek approval. Of 35
LHJs not planning to seek approval, the top four reasons were: limited health
department time (40%) or interest (34%), pharmacy disinterest (31%), and law
enforcement opposition (26%). Among eight LHJs pursuing approval, the main
barriers were “time management” (13%), educating stakeholders (13%), and enlisting
pharmacy participation (13%). The17 LHJs with DPDP represent 52% of California’s
residents; they included 62% of persons living with HIV and 59% of IDU-related HIV
cases, suggesting that many LHJs with significant numbers of HIV cases have approved
DPDPs. Outcome studies are needed to determine whether SB 1159 had the desired
impact on increasing syringe access and reducing blood-borne viral infection risk
among California IDUs.
KEYWORDS Injection drug use, Harm reduction, Syringe access, HIV, Hepatitis C virus,
Health policy
Garfein, Pavlinac, and Haye are with the Department of Medicine, Division of Global Public Health,
School of Medicine, University of California, San Diego, CA, USA; Stopka and Ross are with the
Ofﬁce of AIDS, Center for Infectious Diseases, California Department of Public Health, Sacramento,
CA, USA; Riley is with the Department of Medicine, University of California, San Francisco, CA,
USA; Bluthenthal is with the Urban Community Research Center, Sociology Department, California
State University Dominguez Hills, Santa Monica, CA, USA, and the Health Program and Drug Policy
Research Center, RAND Corporation, Santa Monica, CA, USA; Haye is with the Department of
Pediatrics, University of California San Diego, San Diego, CA, USA.
Correspondence: Richard S. Garfein, PhD, MPH, Division of Global Public Health, Department of
Medicine, University of California San Diego, 9500 Gilman Drive, mailstop 0507, San Diego, CA
92093-0507, USA. (E-mail: rgarfein@ucsd.edu)
Source of Support This study was funded by the Ofﬁce of AIDS (OA), Center for Infectious
Diseases, California Department of Public Health (CDPH) (grant #06-55589).
576
INTRODUCTION
Injection drug use is the second leading cause of HIV and the leading cause of
hepatitis C virus (HCV) infection in California.1 According to California HIV/AIDS
surveillance data, injection drug use accounts for 10.4% of all newly reported AIDS
cases and 19.1% of cases when male injection drug users (IDUs) who also report
having sex with men are included.2 Similarly, injection drug use is the primary risk
factor for HCV infection, likely accounting for more than 60% of prevalent cases
and most incident cases in the USA.3 An estimated 600,000 Californians, or 2% of
the state’s population, are infected with HCV, of which 475,000 Californians are
currently living with chronic hepatitis C in California.4 In San Francisco, 45% of
IDUs under 30 years of age have HCV antibody,5 and among IDUs who injected
longer than 6 years, 71% are anti-HCV positive.6 Young IDUs in San Francisco
are at high risk for HCV infection with an annual incidence of 26.7%.7
Transmission of these and other blood-borne infections occurs through sharing
syringes and other injection paraphernalia that are contaminated with HCV or
HIV-infected blood.8,9
While cessation of injection drug use is the ideal prevention strategy, this is not
always achievable, and studies indicate that making sterile syringes readily available
to IDUs decreases the prevalence of blood-borne viral infections10,11; thus, the US
Public Health Service recommends one-time use of sterile syringes for IDUs who
continue to inject.12 Other studies found lower HIV infection rates and risky
injection practices among IDUs in US cities without laws requiring a prescription
compared to cities with prescription laws.11,13 Efforts to increase syringe access
include syringe exchange programs (SEPs); however, reported barriers to accessing
SEPs include fear of being labeled as an IDU, police harassment, inadequate syringe
supply, limited operating hours, limited privacy, and long travel distance.14
Nonprescription syringe sales (NPSS) provide an important adjunct to SEPs as a
source of sterile syringes.15
Senate Bill 1159 (SB 1159) (Chapter 608, Statutes of 2004)16 was signed into
legislation and enacted on January 1, 2005. According to the legislation, “The
Disease Prevention Demonstration Project (DPDP) is authorized for the purpose of
evaluating the long-term desirability of allowing licensed pharmacists to furnish or
sell nonprescription hypodermic needles or syringes to prevent the spread of blood-
borne pathogens, including HIV and hepatitis C.” Participation in the program is
voluntary, and a two-step “opt-in” process was required before syringes can be
legally sold without a prescription. The ﬁrst step permits local health jurisdictions
(LHJs) to establish DPDPs after approval by a local governing body. The second step
requires pharmacies in LHJs with a DPDP to register with the local health
department (LHD) before they may legally sell ≤10 syringes to customers ≥18 years
old without a prescription. California’s two-step “opt-in” process offers a unique
contrast to other states that have legalized NPSS on a statewide basis, without
requiring additional local approval.
SB 1159 also decriminalized possession of ≤10 syringes obtained from an
authorized source such as a pharmacy. Under the DPDP, registered pharmacies must
provide customers a mechanism for safe disposal of used syringes and information
about HIV prevention and drug treatment. LHDs must maintain lists of registered
pharmacies and provide pharmacies with printed educational materials for their
customers. Without new legislation, SB 1159 provisions will sunset on December 31,
2010.
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To monitor the approval and implementation status of DPDPs statewide, we
surveyed California LHJs annually between 2005 and 2007. California is divided in
to 61 LHJs served by 58 county and three city health departments (Pasadena,
Berkeley, and Long Beach). Results from the 2005 survey were published
previously.17 Data from the past three surveys were used to describe the current
state of the DPDPs 3 years after SB 1159 passed and to elucidate trends in DPDP
approval and implementation.
METHODS
Between 2005 and 2007, three annual surveys were conducted among health
departments in California’s 61 LHJs. Questionnaires were initially sent to health
ofﬁcers in each LHJ and support garnered during meetings of the California
Conference of Local Health Ofﬁcers, the California Conference of Local AIDS
Directors, and the County Health Executives Association of California. Alternate
respondents were requested when someone other than the health ofﬁcer was
primarily responsible for DPDP activities. Questionnaires also requested contact
information for the person who would be most appropriate for future surveys.
Through this process, we were able to identify individuals most knowledgeable
about SB 1159.
Methods for the 2006 and 2007 surveys were similar to the 2005 survey,
reported elsewhere.17 Surveys were mailed and e-mailed to health ofﬁcials with CA
Ofﬁce of AIDS endorsement. An online survey option was added in 2007.
Nonresponders received reminder letters followed by phone calls when needed to
assure high response rates. Responses could be returned by mail, fax, e-mail,
internet, or telephone.
The questionnaire was developed in consultation with an advisory board
founded in 2004 and comprised of state and local public health ofﬁcials, academic
researchers, pharmacists, law enforcement, waste management representatives, and
IDU advocates. Questionnaire topics included DPDP approval and implementation
status, program characteristics, facilitators, and barriers to approval and imple-
mentation, pharmacy registration status, syringe disposal, and technical assistance
needs. We used 2007 data to describe the current status of SB 1159, while data from
all 3 years were used to describe trends in approval and implementation of DPDPs
over time. To assess whether DPDPs were approved in communities needing HIV
prevention, we compared DPDP coverage to 2007 California population estimates
(California Department of Finance)18 and cumulative HIV statistics.2
RESULTS
Overall, 57 (93.4%) LHJs responded in 2005, 55 (90.2%) responded in 2006, and
60 (98.4%) responded in 2007. One LHJ (City of Pasadena) did not respond in
2007 but participated in Los Angeles County’s DPDP. Respondents in 2007
consisted of health department staff (33%), health ofﬁcers and deputy health
ofﬁcers (30%), public health executives (15%), HIV/AIDS program coordinators/
directors (12%), and public health nurses (10%).
By December 2007, DPDPs were approved in 17 (27.9%) LHJs, reﬂecting an
89% increase from 2005 and a 21% increase from 2006 (Table 1). The number of
LHJs in the process of seeking local government approval for a DPDP declined in
2007 compared to 2006 and 2005 (one, two, and eight LHJs, respectively).
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Additionally, the number of LHJs planning, though not actively proceeding, to
approve a DPDP also declined in 2007 compared to 2006 and 2005 (seven, nine,
and 17 LHJs, respectively). Given that the number of LHJs without plans to approve
a DPDP increased in 2007 compared to 2006 and 2005 (35, 25, and 18 LHJs,
respectively), it appears that by 2007, most LHJs considering DPDPs had either
already received local government approval or abandoned plans to do so.
Examining pharmacy registration by year revealed that by 2007, 14 (82%) of the
17 approved DPDPs had registered pharmacies into the program; however, the
proportion of pharmacies that were registered within each LHJ varied from 0% to
61% (Table 2). Of note, the Santa Cruz County Board of Supervisors approved a
DPDP in 2005 for cities within the unincorporated areas of the county, but the cities
were held responsible by the county for also authorizing the program. As of 2007,
no pharmacies had been registered.
A comparison of survey data to California Population and HIV Case Reporting
data revealed that approximately 52% of California’s population resided in the 17
LHJs with DPDPs (Table 3). These LHJs included 62% of reported persons living
with HIV and 59% of IDU-related HIV cases. LHJs with no plans to approve a
DPDP represent approximately 43% of California’s population, 32% of reported
persons living with HIV, and 35% of IDU-related HIV cases. Although California’s
most populous LHJ (Los Angeles) has a DPDP, the next four most populous LHJs
(Orange, Riverside, San Diego, and San Bernardino Counties), including over 10
million residents, do not.
Of the 35 LHJs without plans to approve DPDPs in 2007, 40% cited
“competing priorities-limited time” as a reason for not approving a DPDP.
Additionally, “competing priorities-limited interest” (34%), “lack of pharmacy
interest” (31%), and “law enforcement opposition” (26%) were other major
reasons for not approving DPDPs. The greatest implementation challenges for the
17 LHJs with DPDPs were: “time management” (24%), “enlisting pharmacy
participation” (24%), and “securing DPDP approval” (24%). Similarly, the eight
LHJs planning or in the process of approving a DPDP cited “time management”
(13%); “educating stakeholders” such as police, pharmacists, policy makers, and
community members (13%); and “enlisting pharmacy participation” (13%) as
barriers to approval.
Syringe disposal costs and SEP presence were also examined because these
factors may be considered by governing boards deciding on DPDP approval. In
2007, respondents estimated that DPDP costs for syringe disposal ranged from $0 to
$850 per month. Costs were reportedly absorbed by “integration into existing waste
TABLE 1 Disease Prevention Demonstration Project (DPDP) status by year among California’s
61 local health jurisdictions
DPDP status 2005 2006 2007
Approved 9 14 17
In process of approving 8 2 1
Plan to approve 17 9 7
Approval process on hold 2 0 0
No plans to approve 18 25 35
Status unknown 3 5 0
Survey not completed 4 6 1
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management” (29%), “subsidization by local health department” (21%), and
“surcharges added to syringe price” (7%); 21% reported that “syringe disposal
posed no additional cost.” As of July 2007, California had 39 SEPs operating in 17
LHJs,19 13 (76.5%) of which overlapped with the 17 LHJs with DPDPs versus ﬁve
(11.6%) SEPs in the 43 LHJs surveyed without a DPDP.
Evaluating technical assistance needs and coalition status across all 60 LHJs in
2007 revealed that only 15 (25%) received technical assistance for SB 1159 during
the previous year from: OA (80%), peers in other LHJs (53%), website developed
by OA20 (40%), and other sources (20%). Eight (47%) of the 17 LHJs with a DPDP
had established coalitions to assist with DPDP approval and implementation, while
only ﬁve (11.6%) out of 44 LHJs without DPDPs formed coalitions.
DISCUSSION
Annual surveys conducted during the ﬁrst 3 years since SB 1159 passage revealed
that by December 2007, only 17 of California’s 61 LHJs had approved DPDPs, in
which less than one ﬁfth of the pharmacies had registered to sell nonprescription
syringes. Most DPDPs were authorized shortly after SB 1159 passed and few
additional LHJs still considered implementing DPDPs 3 years after passage. While
only a quarter of the California’s LHJs approved DPDPs, over 52% of the state’s
population and 62% of persons living with HIV were represented in this pilot,
giving credence to the generalizability of ﬁndings from additional studies assessing
TABLE 2 Pharmacies registered by year among 17 local health jurisdictions with approved
Disease Prevention Demonstration Projects
LHJ Approval date
N (%)a pharmacies registered
2005 2006 2007
Contra Costa Dec. 2004 32 (22) 62 (43) 64 (42)
Yuba Jan. 2005 3 (38) 3 (38) 3 (38)
Marin Mar. 2005 12 (35) 13 (37) 14 (41)
Alameda/Berkeleyb Mar. 2005 41 (19) 75 (34) 66/6 (33)
Santa Cruz Mar. 2005 – – 0 (0)
San Francisco Apr. 2005 35 (26) 64 (49) 71 (55)
Yolo May 2005 10 (42) 19 (76) 17 (61)
Los Angeles (city) Jun. 2005 – – 183 (11)
Santa Barbara Sept. 2005 – – 23 (38)
Solano Sept. 2005 – 15 (29) 15 (29)
Humboldt Oct. 2005 – – 0 (0)
San Mateo Dec. 2005 – – 0 (0)
Santa Clara Jan. 2006 – 6 (2) 53 (21)
San Luis Obispo Mar. 2006 – – 1 (2)
Sonoma Sept. 2006 – 6 (9) 6 (9)
Sacramento (city) Dec. 2006 – – 10 (5)
Total 133 (23.6) 263 (28.2) 532 (17.8)
aPercentages were calculated by dividing the number of registered pharmacies by the number of
commercial, non-clinic-based, pharmacies licensed by the California Board of Pharmacy in the county during the
year of the survey
bAlameda and Berkeley are classiﬁed as independent LHJs, but total pharmacy data are aggregated between
the two
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the impact of SB 1159. Since lack of time, resources, and interest were reported by
several health departments as reasons for not approving DPDPs, future legislation
void of the two-step “opt-in” process required during the pilot might permit a
greater number of pharmacies statewide to sell syringes without a prescription as a
way to reduce the risk of HIV and HCV transmission among IDUs.
Local governing bodies, informed by their health ofﬁcials, may be better suited
than the state government to understand the need for NPSS depending on factors
such as prevalence of injection drug use or HIV infection, availability of alternate
interventions, and public approval. Hence, SB 1159 allowed LHJs autonomy to
decide whether or not NPSS would best serve the needs of individual communities
within the country’s most populous state. As the only state in the USA that requires
local government approval before pharmacists can sell nonprescription syringes,
California provides unique insights into NPSS legislation. Results from this study
suggest that while the opt-in process allowed some LHJs to exercise their authority
to keep NPSS illegal, some LHJs may have opted out simply because they lacked the
time or resources to pursue the approval process. In addition, anecdotal reports
from health ofﬁcials indicated that that the opt-in process led to program
inconsistency across LHJs, making it difﬁcult for health departments to help one
another to implement the law and avoid redundancy. This same pattern of
inconsistent implementation was observed for SEP implementation in California; a
process that also required local governing bodies to opt into approving SEPs.21
It is too early to determine the impact of NPSS on pharmacies and consumers in
the 14 LHJs with registered pharmacies. However, Cooper and colleagues22 found
through a survey of pharmacists in San Francisco and Los Angeles Counties that
there have been few problems related to NPSS and that pharmacists were more
likely to sell syringes without a prescription if they considered it an important HIV
prevention intervention. There is also evidence from other states that NPSS decreases
syringe sharing and acquisition from unsafe sources.23–26 Conversely, despite having
pharmacies registered to sell nonprescription syringes, pharmacists’ beliefs and
TABLE 3 Disease Prevention Demonstration Project authorization status by population,
reported living HIV cases and reported living cases attributed to IDU exposure among
California’s 61 local health jurisdictions as of December, 2007
California population Living with HIV
HIV cases attributed to IDU
exposure
N (%) N (%) N (%)
Authorized already 19,680,200 (51.7) 15,160 (62.0) 2,099 (59.4)
In process of obtain-
ing approval
492,642 (1.3) 1,163 (4.8) 142 (4.0)
Not in process but
plan to
1,388,209 (3.6) 228 (0.9) 47 (1.3)
No plans to obtain
approval
16,340,285 (42.9) 7,846 (32.1) 1,239 (35.0)
Did not complete
survey
148,126 (0.4) 69 (0.3) 8 (0.2)
Total 38,049,462 (100) 24,466 (100) 3,535 (100)
Source: California Department of Public Health, Ofﬁce of AIDS, HIV/AIDS Case Registry Section; and State of
California, Department of Finance
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attitudes may hinder IDUs from actually purchasing them as one study found
pharmacists unwilling to sell syringes to certain customers discriminating by race or
other factors.27 In other studies, pharmacists opinion’s toward syringe sale varied
according to their perceptions of whether NPSS prevents HIV or increases drug use,
and their concerns about how selling syringes to IDUs will affect their business and
the community.28–30 Riley and colleagues31 found that 2 years after legalizing NPSS
in San Francisco, pharmacies effectively augmented SEPs as a source of clean
syringes for IDUs. However, it is unknown whether IDUs at highest risk for blood-
borne infections are aware of the law or are able to afford syringes from pharmacies.
Among IDUs enrolled in a treatment facility in New York where NPSS was legalized
in 2001, less than 50% of the sample was aware that they could obtain syringes
from pharmacies and even fewer actually did so.32 Additional pharmacy and
consumer-level assessments of SB 1159 are needed to determine the impact of the
DPDPs in California. Since SB 1159 required an evaluation without a provision for
state funding, such research will depend on alternate state or federal funding.
In 2005, strong community opposition, competing priorities, law enforcement
opposition, and little or no interest among pharmacies were identiﬁed as the major
barriers to SB 1159 approval.17 In 2007, the most commonly reported barriers were
limited time or interest due to competing priorities, suggesting some overlap with the
earlier study, but perhaps also some decrease in opposition. Personal conversations
and open-ended responses to the survey revealed a common emphasis by health
ofﬁcials on the lack of time and resources to develop DPDPs. Of note, LHJs with
SEPs were more likely to approve the DPDP. Future public health legislation should
consider the need for balance between allowing LHJs autonomy to implement
locally suitable policy and overburdening LHJs with an approval process that could
preclude only the most committed communities from adopting it.
This study was limited by potential differences in response quality across LHJs.
Despite the use of a structured questionnaire and thorough follow-up of respondents
in all but one LHJ, respondents’ attention to their answers may vary depending on
whether IDU health issues were signiﬁcant concerns in the respondent’s LHJ.
Another limitation was that we only assessed knowledge possessed by health
department ofﬁcials or staff and not IDUs, pharmacists, or community members. In
2007, an online survey option was added to mailed, faxed, and telephone surveys.
Although this method was believed to make responding easier for some health
ofﬁcials, leading to the highest response rate of the 3 years, we found no evidence
that the online-survey option introduced bias. Further studies are needed to evaluate
the impact of SB 1159 on these groups.
NPSS is intended to increase IDUs’ access to sterile syringes and subsequently
decrease their need to share syringes contaminated with HIV, HCV, or other
bloodborne pathogens.
SB 1159 made it legal for California counties and cities to decide individually
whether or not to remove restrictions on NPSS. This process was similar to
California’s legalization of SEPs and provides an important contrast to other states
that legalized syringe sale or exchange on a statewide basis.21 While SB 1159 gave
localities the choice of legalizing these programs, consequences of this approach
include preventing the willing pharmacies in non-approved LHJs from selling
syringes, complicating technical assistance to LHJs because DPDPs lack uniformity
and possible confusion among consumers about where they can and cannot legally
purchase syringes. While SB 1159 permitted some LHJs to implement NPSS, a
measured response was observed that appears to be due to a mixture of willingness
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and resources across the state’s 61 LHJs. Further research is needed to identify what
conditions, if any, would have made it possible for additional jurisdictions to legalize
nonprescription syringe sales in California.
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